TAI:6919

Caliway Biopharmaceuticals Co. L · TAI · Healthcare · TWD · FY for 2025

Figures on this page computed 2026-11-08 12:49 UTC

Last close

n/aTWD

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
TWD
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
TWD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-925.2%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
TWD
- Computed from the filing for 2025
- Computed from the filing for 2025
-1166.6%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
TWD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.0003Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
TWD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
TWD
- computed

Price is the furthest below its sector's middle: 0.00 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.52x

1.14x

1.58x

0.00x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.52x
Its own average over 7 years, 25.0M.
Profit1.14x
Its own average over 7 years, -308.2M.
Free cash flow1.58x
Its own average over 7 years, -280.2M.
Debt0.00x
Its own average over 7 years, 54.8M.
Pricen/a
Its own average over 0 years. Market data

Debt is furthest from its own average, at 0.00 times.

Sales is 1.52 times its own 7-year average; Profit is 1.14 times its own 7-year average; Free cash flow is 1.58 times its own 7-year average; Debt is 0.00 times its own 7-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 7-year average1.52
Source
computed
Statement
income
Fiscal year
2025
Reported in
TWD
Profit against its own 7-year average1.14
Source
computed
Statement
income
Fiscal year
2025
Reported in
TWD
Free cash flow against its own 7-year average1.58
Source
computed
Statement
income
Fiscal year
2025
Reported in
TWD
Debt against its own 7-year average0.002
Source
computed
Statement
income
Fiscal year
2025
Reported in
TWD
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
TWD